INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 March 23, 2009				Attorney Docket No. 056291-5296 Applicants: David Michael ANDRE			Application No. 10/586,954		
				Filing Date: July 25, 2006			Group Art Unit: 1624		
U.S. PATENT DOCUMENTS									
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date	
						+			
							1		
			EODEICN	PATENT DO	CIT IN A PENING				
		Document No.	Date		ountry	Class	Sub-Class	Translation	
	1.	WO 2004/005282	January 15, 2004		WIPO	Ciass	Sub-Cias	Translation	
	2.	WO 2005/068452	July 28, 2005		WIPO				
	3.	WO 2007/040436	April 12, 2007		WIPO		X		
	4.	WO 2008/002244	January 3, 2008		WIPO				
	5.	WO 2008/002245	January 3, 2008		WIPO				
		OTHER DO	CUMENTS (Include	ling Author T	itle Date P	ertinent Pa	roe atc.)		
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Anderson et al. "Imidazo[1,2-a]pyridines: A potent and selective class of cyclin-dependent kinase inhibitors identified								
	through structure-based hybridisation" Bioorganic & Medicinal Chemistry Letters 13(18):3021-3026 (2003).								
	7. Byth et al. "Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 14(9): 2245-2248 (2004).								
	8.	Byth et al. "Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 14(9): 2249-2252 (2004).							
	9	Professional (The cells by the							
	9.	inhibitor" Molecular Cancer Therapeutics 5(3):655-664 (2006).							

			····						
Examiner		/Deepak Rao/	Date C	onsidered		7/0000			
			i			27/2009			
Examiner: conforman	Initial e and	if reference considered not considered. Include	, whether or not cita copy of this form w	tion is in confo ith next comm	rmance with mication to a	MPEP 609; pplicant.	draw line thr	ough citation if not in	